Tealwood Asset Management Inc. Takes Position in ADMA Biologics Inc $ADMA

Key Points

• Tealwood Asset Management opened a new position in ADMA Biologics by buying 72,087 shares in the fourth quarter, a stake valued at about $1.315 million, while roughly 75.68% of the stock is held by hedge funds and other institutional investors.
• ADMA's latest quarter (released Feb. 25) delivered EPS of $0.20 (in line with estimates) and revenue of $139.16 million (up 18.4% year-over-year but slightly below expectations), and analysts hold an average "Buy" rating with a consensus price target of $32.00.
• Notable insider activity included COO Kaitlin Kestenberg-Messina selling 10,096 shares at about $15.63 and Director Steve Elms purchasing 7,000 shares at about $15.67; insiders now own roughly 3.50% of the company.

Tealwood Asset Management Inc. purchased a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 72,087 shares of the biotechnology company's stock, valued at approximately $1,315,000.

Other large investors have also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC purchased a new stake in ADMA Biologics in the 3rd quarter valued at approximately $25,000. Rothschild Investment LLC increased its position in ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,495 shares during the period. Clearstead Advisors LLC raised its stake in shares of ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company's stock worth $33,000 after buying an additional 795 shares in the last quarter. iSAM Funds UK Ltd acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $34,000. Finally, RiverPark Advisors LLC acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $35,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

ADMA stock opened at $14.32 on Friday. The firm has a 50 day moving average of $16.33 and a 200-day moving average of $16.64. The company has a market cap of $3.41 billion, a price-to-earnings ratio of 23.87 and a beta of 0.51. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. ADMA Biologics Inc has a 12-month low of $13.76 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts' consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million for the quarter, compared to analysts' expectations of $139.80 million. During the same quarter in the prior year, the firm posted $0.46 EPS. The company's revenue was up 18.4% compared to the same quarter last year. As a group, equities analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

ADMA has been the topic of a number of analyst reports. Weiss Ratings restated a "hold (c)" rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Zacks Research raised ADMA Biologics from a "hold" rating to a "strong-buy" rating in a report on Monday, March 2nd. Finally, Wall Street Zen upgraded shares of ADMA Biologics from a "hold" rating to a "buy" rating in a research report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $32.00.

Insiders Place Their Bets

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the transaction, the chief operating officer owned 466,600 shares of the company's stock, valued at $7,292,958. The trade was a 2.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Steve Elms acquired 7,000 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The stock was acquired at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the transaction, the director directly owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 3.50% of the stock is currently owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.